CurrentCapital BluecrossPolicy AHS G201

Diagnostic Testing of Iron Homeostasis & Metabolism

Defines coverage criteria for laboratory testing of iron homeostasis/metabolism (serum ferritin, transferrin saturation, hepcidin, GlycA) including indications, limitations, and frequency for monitoring iron overload, iron deficiency, specific diseases (hemochromatosis, HLH, Still disease, CKD, liver disease), and relatives of affected individuals. Part 1 covers policy description, indications/limitations, terminology, scientific background, validity, clinical utility, and guideline citations.

Policy Summary

PayerCapital Bluecross

PolicyDiagnostic Testing of Iron Homeostasis & Metabolism

Policy CodePolicy AHS G201- Diagnostic Testing of Iron Homeostasis and Metabolism

Change TypeNo material change

Effective DateApr 1, 2025

Next Review Date

Key ActionProviders should document the clinical indication that fits covered criteria (e.g., abnormal hemoglobin/hematocrit, suspected iron overload, symptoms of hemochromatosis, first-degree relative with HH, liver disease, HLH/Still disease, CKD anemia management, on iron therapy); testing for other indications may be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this update.

2Tests explicitly not covered (hepcidin, GlycA)

2Primary tests covered with criteria (serum ferritin, transferrin saturation)

10Covered clinical indications listed for ferritin

6Guideline Sources Cited

6Reference CPT/HCPCS Codes Listed

3Key Test Thresholds Specified

Coverage Summary

Scope: Policy AHS G201 (effective 2025-04-01) defines coverage for diagnostic testing of iron homeostasis and metabolism (serum ferritin, transferrin/transferrin saturation, hepcidin, and GlycA) including indications, limitations, frequency for monitoring iron overload and deficiency, and related terminology and guidance.

Coverage stance (mixed): Serum ferritin (SF) and transferrin saturation (TSAT) are covered when specific criteria/indications are met (examples: abnormal hemoglobin/hematocrit, suspected iron overload or hemochromatosis symptoms, first‑degree relatives of confirmed hereditary hemochromatosis, liver disease, HLH/Still disease, CKD anemia management, monitoring on iron therapy; monitoring frequency guidance also provided).

Not covered: Serum hepcidin testing (including immunoassays) and GlycA testing do not meet coverage criteria due to insufficient published evidence of clinical benefit.

Policy number: AHS G201. Reference CPT/HCPCS codes listed (examples include 83540, 83550, 84466, 0024U, 0251U, 84999).

High‑level covered vs not covered summary: primary tests covered with criteria are SF and TSAT (covered for listed clinical indications and monitoring intervals); tests explicitly not covered are hepcidin and GlycA (lack of evidence). Numeric highlights from stats: tests explicitly not covered = 2; primary tests covered with criteria = 2.

Policy metadata

Policy numberAHS G201

Effective date2025-04-01

Last review2015-11-16

StatusCURRENT

SubjectDiagnostic testing of iron homeostasis and metabolism (serum ferritin, transferrin saturation, hepcidin, GlycA)

Scope summaryDefines coverage criteria for laboratory testing of iron homeostasis/metabolism (serum ferritin, transferrin saturation, hepcidin, GlycA) including indications, limitations, and frequency for monitoring iron overload, iron deficiency, specific diseases (hemochromatosis, HLH, Still disease, CKD, liver disease), and relatives of affected individuals. Part 1 covers policy description, indications/limitations, terminology, scientific background, validity, clinical utility, and guideline citations.

Medical-Necessity Criteria

Medically Necessary / Meets Coverage Criteria

Measurement of serum ferritin and transferrin saturation meets coverage criteria in the following situations:

Serum ferritin measurement meets coverage when ANY of the following are met

For the evaluation of an individual with abnormal hemoglobin and/or hematocrit levels
For the evaluation and monitoring of iron overload disorders
For individuals with symptoms of hemochromatosis (see Note 1)
See Note 1 for symptoms
For individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH) (see Note 2)
See Note 2: parents, full siblings, and children

Key Thresholds & Definitions

Key thresholds

Ferritin absolute iron deficiency cutoff< 30 ng/mL

TSAT absolute iron deficiency cutoff< 20%

Ferritin inflammatory-state cutoff< 100 ng/mL

AGA ferritin recommendation for anemia cutoffUse 45 ng/mL instead of 15 ng/mL

Therapeutic phlebotomy ferritin indication> 1000 ng/mL

HLH ferritin diagnostic level (study)3951 ng/mL

WHO risk of overload cutoffsFemales >150 ug/L; Males >200 ug/L; Infection/inflammation >500 ug/L

Coding

Applicable CPT/HCPCS procedure codes (reference list)mixed

83540	Ferritin
83550	Iron binding capacity
84466	Transferrin
84999	Unlisted chemistry procedure
0024U	GlycA, nuclear magnetic resonance spectroscopy, quantitative (Proprietary test: GlycA)
0251U	Hepcidin-25, ELISA (Proprietary test: Intrinsic Hepcidin IDx Test)

Provider Actions & Billing Guidance

Documentation Required

Indication documentation for ferritin/TSAT testing

Document the clinical indication that fits covered criteria before ordering ferritin or TSAT. Examples of covered indications include abnormal hemoglobin/hematocrit, suspected iron overload, symptoms of hemochromatosis, first‑degree relative with confirmed hereditary hemochromatosis, liver disease, HLH/Still disease, CKD anemia management, and individuals on iron therapy.

Abnormal hemoglobin or hematocrit
Suspected iron overload
Symptoms of hemochromatosis
First‑degree relative with confirmed hereditary hemochromatosis
Liver disease evaluation
HLH or Still disease evaluation
CKD anemia management
On iron therapy

Supporting Evidence & Guidelines

Citation	Key point
Dahlfors 2015	Competitive ELISA hepcidin correlates with LC‑MS/MS (r=0.89) but cross‑reacts with hepcidin forms (analytical limitation)
Chen 2019	HPLC‑MS/MS hepcidin method with high analytical precision: intra‑day CV <3% and inter‑day CV <6%
Garcia‑Casal 2021 (meta‑analysis)	Serum/plasma ferritin is reasonably sensitive and very specific for detecting iron deficiency; very low certainty that high ferritin is sensitive for detecting overload in asymptomatic people
Auerbach 2021	RET‑He identifies iron deficiency with sensitivity 68.2% and specificity 69.7% and predicts IV iron responsiveness (clinical utility adjunct)
ICCAMS (International Consensus on Peri‑operative Anemia)	Defines absolute iron deficiency as ferritin <30 ng/mL and/or TSAT <20%; ferritin <100 ng/mL may indicate deficiency in inflammatory states; recommends reticulocyte Hb or hepcidin if available in inflammatory states
KDIGO / KDOQI / ISN (CKD anemia guidelines)	Recommend baseline and periodic TSAT and ferritin testing in CKD; during ESA therapy test at least every 3 months and more frequently when initiating/increasing ESA or after IV iron; KDOQI: once per month during initial treatment then ≥every 3 months when stable
ECCO (IBD guidelines)	Recommend CBC, serum ferritin, and CRP for screening; measure every 6–12 months in remission and ≥every 3 months in active disease; ferritin cutoffs adjusted for inflammation (≤30 µg/L in remission, ≤100 µg/L may still indicate deficiency in active inflammation)
USPSTF	Evidence insufficient (Grade I) to recommend routine screening for iron deficiency anemia in pregnancy or universal screening in young children
ASH (Iron Overload guidance)	Serum ferritin commonly used to monitor iron chelation; recommend frequent checks (every 3–6 weeks) to calculate running averages; TSAT >85% associated with NTBI risk but NTBI/LPI remain research/adjunct markers
Applicable CPT/HCPCS codes (policy list)	Codes referenced for tests: 83540 (ferritin), 83550 (TIBC), 84466 (transferrin), 0251U (hepcidin‑25 ELISA), 0024U (GlycA NMR), 84999 (unlisted) — provided as reference

Revision History

Policy Summary

PayerCapital Bluecross

PolicyDiagnostic Testing of Iron Homeostasis & Metabolism

Policy CodePolicy AHS G201- Diagnostic Testing of Iron Homeostasis and Metabolism

Change TypeNo material change

Effective DateApr 1, 2025

Next Review Date

SourceLink

On This Page

For the evaluation of individuals with liver disease

For the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease

In males with secondary hypogonadism

At a frequency of every 1 to 3 monthsEvery 1 to 3 months

Frequency likely pertains to monitoring contexts

For the evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for receiving treatment for anemia

For individuals on iron therapy

Serum transferrin saturation (TSAT) measurement meets coverage when ANY of the following are met

For the evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1)
See Note 1 for symptoms
For the evaluation of iron overload in individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH) (see Note 2)
See Note 2: parents, full siblings, and children
For the evaluation of iron deficiency anemia

Transferrin saturation safety threshold for NTBI risk> 85%

Reticulocyte Hb suggestive of iron deficiency< 29 pg

Serum hepcidin suggestive of iron deficiency (if available)< 20 (units per source)

First‑degree relatives: parents, full siblings, and children of the individual.

SF (Serum ferritin): circulating ferritin measured in serum; reflects iron storage in healthy adults but is an acute phase reactant that increases with inflammation, liver disease, malignancy and other causes, which can mask iron deficiency.

TSAT (Transferrin saturation): the percent of transferrin iron‑binding sites occupied by iron; used with ferritin to assess iron availability and to evaluate iron overload or iron deficiency.

NTBI / LPI (Non‑transferrin‑bound iron / labile plasma iron): research/adjunctive markers that may indicate circulating, redox‑active iron when transferrin saturation is very high and are attractive for toxicity risk assessment but currently lack large validation for routine monitoring.

GlycA: a composite NMR biomarker of systemic inflammation (CPT 0024U) that measures acetyl methyl groups on plasma glycoproteins; analytical limitations include signal overlap and inability to distinguish contributions of individual glycoproteins (so it cannot accurately quantify transferrin).

Brief assay limitations: hepcidin assays show method variability—ELISA may cross‑react with other hepcidin forms despite correlation with LC‑MS/MS, while LC‑MS/MS methods have lower imprecision but hepcidin testing overall lacks sufficient evidence for coverage; GlycA requires deconvolution due to spectral overlap and provides only a rough estimate of contributing proteins.

Iron biology: dietary iron is absorbed by enterocytes (non‑heme via DMT1, heme via receptor‑mediated uptake), exported by ferroportin and bound in plasma by transferrin for delivery to erythroid precursors; intracellular iron is stored in ferritin and released by ferritinophagy when needed. Hepcidin, produced in response to iron and inflammatory signals, binds ferroportin causing its degradation and thereby decreases iron export into plasma.

Ferritin as acute phase reactant: serum ferritin generally reflects iron stores in healthy individuals but is also upregulated by oxidative stress and inflammation and can be elevated in liver disease, malignancy, chronic alcohol use, and other inflammatory states—therefore normal or elevated ferritin does not exclude iron deficiency in inflammatory conditions.

Analytical and utility limitations: hepcidin assays vary by method—competitive ELISAs may cross‑react with hepcidin isoforms though correlate with LC‑MS/MS, and LC‑MS/MS methods have low intra/inter‑day CVs; despite improving analytic validity, hepcidin testing currently lacks sufficient evidence of clinical utility for routine coverage. GlycA NMR measurement is limited by spectral overlap and cannot resolve contributions of individual glycoproteins, limiting its use to a nonspecific inflammation biomarker rather than transferrin quantification.

Documentation Required

Family history documentation

When ordering hereditary hemochromatosis testing for relatives, document the family relationship and that the relative is a first‑degree family member (parent, full sibling, or child) of an individual with confirmed hereditary hemochromatosis.

Documentation Required

Account for inflammation in interpretation

Document inflammatory status (e.g., CRP) when interpreting ferritin because ferritin is an acute phase reactant and can be elevated by inflammation, liver disease, malignancy, or other inflammatory states; note that in inflammatory conditions higher ferritin thresholds apply and normal ferritin does not exclude iron deficiency.

Billing Rule

Monitoring frequency

Ferritin monitoring may be covered at a frequency of every 1 to 3 months where clinically indicated; apply this interval for routine monitoring unless guideline‑based indications call for different frequency.

Documentation Required

Testing frequency for CKD/ESA therapy

For patients with CKD receiving or being considered for ESA therapy, order TSAT and ferritin at least every 3 months; test more frequently when initiating or increasing ESA dose, after IV iron, with blood loss, or when iron stores may change.

Documentation Required

Monitoring during iron chelation

When monitoring iron chelation therapy, check serum ferritin frequently (every 3–6 weeks) so running averages can be calculated to account for variability and transient fluctuations.

Billing Rule

Use listed CPT codes for lab procedures

Report appropriate laboratory procedure codes as applicable; the policy lists these codes for reference only.

83540
83550
84466
0024U
0251U
84999

Documentation Required

Follow government coverage precedence

If this policy conflicts with applicable government policies (e.g., NCD, LCD, or state Medicaid rules) for a Medicare or Medicaid member, follow the government policy precedence.